Kyung Dong Pharmaceutical Co. Ltd
Kyung Dong Pharmaceutical Co., Ltd. produces and sells specialized and general medicines in South Korea. It offers prescription medicines for liver therapy, antispasmodic, antidiabetic, antiviral, corticosteroid, androgen alopecia, muscle relaxant, antimigraine, vitamin, antifungal, endocrinal, urology, antibacterial, cardiovascular, pain/inflammation, smoking cessation aid, gastrointestinal, ant… Read more
Kyung Dong Pharmaceutical Co. Ltd (011040) - Total Liabilities
Latest total liabilities as of September 2025: ₩74.22 Billion KRW
Based on the latest financial reports, Kyung Dong Pharmaceutical Co. Ltd (011040) has total liabilities worth ₩74.22 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kyung Dong Pharmaceutical Co. Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Kyung Dong Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kyung Dong Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Kyung Dong Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Silk Logistics Holdings Ltd
AU:SLH
|
Australia | AU$479.39 Million |
|
Peter Warren Automotive Holdings Ltd
AU:PWR
|
Australia | AU$917.75 Million |
|
Saksiam Leasing Public Company Limited
BK:SAK
|
Thailand | ฿9.23 Billion |
|
Tembo Global Industries Limited
NSE:TEMBO
|
India | ₹4.27 Billion |
|
T.K.S. Technologies Public Company Limited
BK:TKS
|
Thailand | ฿1.04 Billion |
|
ImageneBio, Inc.
NASDAQ:IMA
|
USA | $21.05 Million |
|
Cameo Communications Inc
TW:6142
|
Taiwan | NT$1.20 Billion |
|
ReaLy Development & Construction
TWO:2596
|
Taiwan | NT$3.20 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Kyung Dong Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kyung Dong Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kyung Dong Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual total liabilities of Kyung Dong Pharmaceutical Co. Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩82.81 Billion | +28.40% |
| 2023-12-31 | ₩64.49 Billion | +21.06% |
| 2022-12-31 | ₩53.27 Billion | +65.69% |
| 2021-12-31 | ₩32.15 Billion | +10.09% |
| 2020-12-31 | ₩29.21 Billion | -52.03% |
| 2019-12-31 | ₩60.88 Billion | +32.14% |
| 2018-12-31 | ₩46.08 Billion | +51.20% |
| 2017-12-31 | ₩30.47 Billion | +6.69% |
| 2016-12-31 | ₩28.56 Billion | +1.01% |
| 2015-12-31 | ₩28.28 Billion | -24.09% |
| 2014-12-31 | ₩37.25 Billion | +18.80% |
| 2013-12-31 | ₩31.35 Billion | -11.62% |
| 2012-12-31 | ₩35.48 Billion | +1.06% |
| 2011-12-31 | ₩35.10 Billion | -- |